...
首页> 外文期刊>International braz j urol >Primary large cell prostate neuroendocrine carcinoma with central and nephrogenic diabetes insipidus
【24h】

Primary large cell prostate neuroendocrine carcinoma with central and nephrogenic diabetes insipidus

机译:中枢大细胞前列腺神经内分泌癌,中枢和肾糖尿病胰腺炎

获取原文

摘要

Neuroendocrine carcinoma of the prostate (PNEC) is rare and accounts for less than 0.5% of all prostate neoplasms (1). These tumors can be subdivided into small cell carcinomas, large cell neuroendocrine carcinomas (LCNEC) and carcinoid tumors based on the morphologic characteristics and proliferative index of tumors. PNEC is often diagnosed after long-lasting androgen deprivation therapy (ADT) for previous prostate adenocarcinoma (2). However, the pure form of this tumor is exceedingly rare and associated with aggressive behavior. Only a few cases with primary LCNEC have been published and its clinical course and treatment options remain unclear, yet (2, 3). In this study, we aim to report an unusual case of primary LCNEC with dexamethasone induced nephrogenic diabetes insipidus (NDI) during its management.
机译:前列腺癌(PNEC)的神经内分泌癌是罕见的,占所有前列腺肿瘤的0.5%(1)。这些肿瘤可根据肿瘤的形态特征和增殖指数细分为小细胞癌,大细胞神经内分泌癌(LCNEC)和类癌肿瘤。在以前的前列腺腺癌(2)的持久性雄激素剥夺治疗(ADT)后通常诊断为PNEC。然而,这种肿瘤的纯形式非常珍稀,与侵略性行为有关。仅发布了少数LCNEC的少数案例,其临床课程和治疗方案仍然尚不清楚(2,3)。在这项研究中,我们的目标是在管理期间向地塞米松诱导的肾上腺发生肾病患者(NDI)报告原发性LCNEC的不寻常情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号